Hospital
Glendale Adventist Medical Center
Glendale Adventist Medical Center was paid $52.82M by Medicaid between Jan 2018 and Dec 2024, across 406 billing codes. Its largest line is 0450, Emergency room services — 19% of everything it billed.
33Billing provider infoGLENDALE ADVENTIST MEDICAL CENTER
GLENDALE, CA 91206
GLENDALE, CA 91206
33aNPI1831188275assigned 10/18/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$52.82M
24GClaims1,503,452
24DCodes billed406
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#57 of 410
Median peer was paid$6.90M
This provider vs. median7.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 242,146 | $7.27M | |
| 2019 | 208,400 | $8.20M | |
| 2020 | 148,165 | $5.40M | |
| 2021 | 167,438 | $6.66M | |
| 2022 | 208,349 | $8.07M | |
| 2023 | 247,739 | $8.74M | |
| 2024incomplete | 281,215 | $8.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 19% | 81,528 | 73,983 | $10.23M |
| 99070 | 9.7% | 15,687 | 8,114 | $5.15M | |
| 80053 | Comprehensive metabolic panel | 4.4% | 61,054 | 55,090 | $2.33M |
| J3490 | Unclassified drugs | 3.1% | 47,979 | 26,293 | $1.64M |
| J7030 | Infusion, normal saline solution , 1000 cc | 2.9% | 25,895 | 23,358 | $1.55M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.0% | 7,583 | 7,034 | $1.06M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 13,194 | 12,509 | $1.02M |
| 99199 | Unlisted special service, procedure or report | 1.7% | 12,349 | 10,746 | $915K |
| 84484 | 1.6% | 33,169 | 27,045 | $861K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.4% | 13,268 | 12,591 | $730K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 1.4% | 9,971 | 8,408 | $725K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.3% | 5,814 | 5,544 | $706K |
394 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 9,651 | $664K |
| 0250 | 1.2% | 10,511 | $620K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 11,211 | $605K |
| 81025 | 1.1% | 20,609 | $579K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 7,156 | $565K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1.1% | 7,939 | $560K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 20,194 | $546K |
| 99284 | Emergency room visit (serious) | <1% | 7,894 | $515K |
| 71045 | Radiologic examination, chest; single view | <1% | 29,319 | $508K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,281 | $478K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,530 | $476K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22,418 | $469K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 19,702 | $456K |
| 59025 | Fetal non-stress test | <1% | 3,959 | $451K |
| 0762 | <1% | 4,286 | $434K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 46,668 | $415K |
| 0360 | <1% | 5,833 | $411K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18,161 | $395K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 7,701 | $382K |
| 0206 | <1% | 522 | $374K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 15,172 | $361K |
| 83605 | <1% | 48,272 | $349K | |
| 99283 | Emergency room visit (moderate) | <1% | 5,906 | $344K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 30,884 | $337K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 11,565 | $323K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,756 | $322K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,946 | $317K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,785 | $315K |
| 73562 | <1% | 4,050 | $301K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,658 | $286K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,228 | $282K |
| 86901 | <1% | 3,838 | $280K | |
| 0121 | <1% | 346 | $273K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 17,476 | $272K |
| 83880 | <1% | 8,845 | $271K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 7,971 | $261K |
| 81001 | <1% | 46,375 | $249K | |
| 73610 | <1% | 2,228 | $239K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,589 | $236K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13,959 | $229K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,672 | $214K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,119 | $208K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,691 | $205K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,361 | $194K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,413 | $184K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,963 | $182K |
| 87081 | <1% | 2,557 | $181K | |
| 0510 | <1% | 7,330 | $176K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,511 | $174K |
| 73030 | <1% | 2,936 | $174K | |
| 0300 | <1% | 4,179 | $167K | |
| 73630 | <1% | 2,354 | $162K | |
| 80143 | <1% | 1,427 | $154K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,039 | $149K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,011 | $144K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 67,402 | $139K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,361 | $138K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 731 | $126K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,806 | $118K |
| 87400 | <1% | 3,288 | $117K | |
| 97139 | <1% | 15,989 | $114K | |
| 72100 | <1% | 3,181 | $114K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,680 | $114K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,961 | $111K |
| 71250 | <1% | 1,566 | $110K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,598 | $109K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,069 | $109K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,668 | $107K |
| 70496 | <1% | 1,708 | $107K | |
| 72131 | <1% | 1,546 | $106K | |
| 97116 | <1% | 6,630 | $105K | |
| 73130 | <1% | 1,683 | $104K | |
| 86850 | <1% | 2,177 | $104K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 588 | $103K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 842 | $101K |
| 0160 | <1% | 2,850 | $96K | |
| 84703 | <1% | 6,044 | $96K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,619 | $95K |
| 76830 | Ultrasound, transvaginal | <1% | 4,000 | $94K |
| 72040 | <1% | 1,337 | $93K | |
| 93970 | <1% | 1,775 | $93K | |
| 70498 | <1% | 1,603 | $90K | |
| 0729 | <1% | 1,161 | $88K | |
| 90715 | <1% | 1,299 | $86K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 746 | $85K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,292 | $85K |
| 75574 | <1% | 1,089 | $84K | |
| 80076 | <1% | 3,939 | $82K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,719 | $82K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,738 | $81K |
| Z9725 | <1% | 2,698 | $81K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,301 | $80K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,423 | $78K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 367 | $78K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,838 | $74K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,342 | $73K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 960 | $73K |
| 93971 | <1% | 2,418 | $73K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,712 | $72K |
| 76641 | <1% | 1,652 | $72K | |
| 73110 | <1% | 1,549 | $70K | |
| 76770 | <1% | 2,029 | $69K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,396 | $68K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,687 | $67K |
| 76801 | <1% | 2,169 | $67K | |
| 97750 | <1% | 3,518 | $65K | |
| 70486 | <1% | 636 | $60K | |
| 87040 | <1% | 16,420 | $58K | |
| 77066 | Tomosynthesis, mammo | <1% | 925 | $57K |
| 0258 | <1% | 4,238 | $55K | |
| 74018 | <1% | 2,100 | $55K | |
| 73080 | <1% | 797 | $54K | |
| 87070 | <1% | 1,949 | $49K | |
| 76536 | <1% | 1,463 | $47K | |
| 84702 | <1% | 2,987 | $47K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 130 | $46K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 373 | $43K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 465 | $42K |
| G0378 | Hospital observation service, per hour | <1% | 390 | $41K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,204 | $41K |
| 83690 | <1% | 18,274 | $41K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 309 | $40K |
| 97162 | <1% | 1,523 | $40K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,864 | $38K |
| 86900 | <1% | 2,578 | $36K | |
| 0710 | <1% | 4,385 | $36K | |
| 0440 | <1% | 860 | $36K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,042 | $35K |
| 20610 | <1% | 3,029 | $35K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,659 | $34K |
| 96367 | <1% | 1,546 | $34K | |
| 0420 | <1% | 2,122 | $33K | |
| 84145 | <1% | 708 | $33K | |
| 73502 | <1% | 1,008 | $33K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,079 | $33K |
| 0259 | <1% | 11,017 | $32K | |
| 0270 | <1% | 25,677 | $32K | |
| 0720 | <1% | 205 | $32K | |
| 72141 | <1% | 194 | $29K | |
| 87186 | <1% | 4,324 | $28K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,425 | $27K |
| Z7502 | <1% | 727 | $27K | |
| 87077 | <1% | 3,840 | $26K | |
| 71101 | <1% | 172 | $26K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,354 | $26K |
| 82962 | <1% | 4,341 | $25K | |
| 82948 | <1% | 4,129 | $25K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,430 | $25K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,475 | $25K |
| 85610 | <1% | 13,438 | $24K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,406 | $24K |
| 73140 | <1% | 576 | $24K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,281 | $23K |
| 97113 | <1% | 758 | $22K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 886 | $22K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 509 | $22K |
| 97161 | <1% | 936 | $21K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,674 | $21K |
| 76818 | <1% | 915 | $20K | |
| 93017 | <1% | 790 | $20K | |
| 73560 | <1% | 1,701 | $20K | |
| 93880 | <1% | 290 | $20K | |
| 97755 | <1% | 499 | $19K | |
| 86308 | <1% | 2,219 | $19K | |
| 83735 | <1% | 9,651 | $18K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,427 | $17K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,374 | $17K |
| 0001A | <1% | 513 | $17K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 951 | $17K |
| 76857 | <1% | 828 | $17K | |
| 97163 | <1% | 343 | $16K | |
| 93458 | <1% | 265 | $16K | |
| 73700 | <1% | 200 | $15K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,959 | $15K |
| 70491 | <1% | 96 | $15K | |
| 74174 | <1% | 83 | $14K | |
| 85379 | <1% | 3,973 | $14K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 627 | $13K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 432 | $13K |
| 85730 | <1% | 8,150 | $13K | |
| 82550 | <1% | 5,322 | $13K | |
| 80179 | <1% | 1,416 | $13K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 247 | $13K |
| 77300 | <1% | 34 | $12K | |
| 0011A | <1% | 309 | $12K | |
| 74022 | <1% | 275 | $11K | |
| 73221 | <1% | 31 | $11K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,867 | $11K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 92 | $11K |
| 87807 | <1% | 616 | $11K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 826 | $11K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,671 | $10K |
| 36430 | <1% | 87 | $10K | |
| 76377 | <1% | 335 | $9K | |
| 96376 | <1% | 196 | $9K | |
| 80061 | Lipid panel | <1% | 5,185 | $9K |
| 0002A | <1% | 298 | $9K | |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 41 | $9K |
| 77080 | <1% | 640 | $9K | |
| 0111 | <1% | 13 | $9K | |
| 88342 | <1% | 782 | $9K | |
| 84439 | <1% | 3,275 | $9K | |
| 76870 | <1% | 289 | $8K | |
| 82378 | <1% | 2,631 | $8K | |
| 0760 | <1% | 2,369 | $8K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 962 | $8K |
| 81003 | <1% | 613 | $8K | |
| 84153 | <1% | 1,064 | $8K | |
| 86769 | <1% | 152 | $8K | |
| 88112 | <1% | 458 | $7K | |
| 99152 | <1% | 1,653 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,327 | $7K |
| 93351 | <1% | 145 | $7K | |
| 29125 | <1% | 545 | $7K | |
| 84481 | <1% | 1,370 | $7K | |
| 82728 | <1% | 2,724 | $6K | |
| 84550 | <1% | 1,060 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,438 | $6K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 688 | $6K |
| 83615 | <1% | 1,852 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,599 | $6K |
| 73590 | <1% | 135 | $5K | |
| 0301 | <1% | 2,357 | $5K | |
| 77334 | <1% | 31 | $5K | |
| 87088 | <1% | 1,912 | $5K | |
| 77336 | <1% | 211 | $5K | |
| 82553 | <1% | 866 | $5K | |
| 0012A | <1% | 128 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 863 | $5K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 247 | $5K |
| 0761 | <1% | 446 | $5K | |
| 93016 | <1% | 594 | $5K | |
| 85027 | <1% | 1,865 | $4K | |
| 93798 | <1% | 187 | $4K | |
| 94664 | <1% | 1,340 | $4K | |
| 92526 | <1% | 101 | $4K | |
| 0324 | <1% | 1,167 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 27 | $4K |
| 88304 | <1% | 708 | $4K | |
| 82150 | <1% | 1,888 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 37 | $3K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,310 | $3K |
| 82784 | <1% | 1,062 | $3K | |
| 72197 | <1% | 28 | $3K | |
| 82570 | <1% | 580 | $3K | |
| 80320 | <1% | 15 | $3K | |
| 84156 | <1% | 446 | $3K | |
| 99221 | <1% | 106 | $3K | |
| 88307 | <1% | 80 | $3K | |
| 85007 | <1% | 1,829 | $3K | |
| 82607 | <1% | 1,594 | $3K | |
| 86140 | <1% | 2,161 | $2K | |
| 93018 | <1% | 618 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 149 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 41 | $2K |
| 0424 | <1% | 56 | $2K | |
| 0370 | <1% | 1,428 | $2K | |
| 0272 | <1% | 780 | $2K | |
| 72170 | <1% | 91 | $2K | |
| 85384 | <1% | 446 | $2K | |
| 84466 | <1% | 1,816 | $2K | |
| 83970 | <1% | 174 | $2K | |
| 77412 | <1% | 123 | $2K | |
| 97799 | <1% | 2,327 | $2K | |
| 82746 | <1% | 1,255 | $2K | |
| 73552 | <1% | 52 | $2K | |
| 72070 | <1% | 40 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 319 | $2K |
| 86300 | <1% | 960 | $2K | |
| 87210 | <1% | 114 | $2K | |
| 87205 | <1% | 641 | $2K | |
| 97166 | <1% | 14 | $1K | |
| 82043 | <1% | 515 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 25 | $1K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 170 | $1K |
| 87641 | <1% | 272 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 195 | $1K |
| 0430 | <1% | 315 | $1K | |
| 85652 | <1% | 1,720 | $1K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 130 | $1K |
| 95811 | <1% | 13 | $1K | |
| 83540 | <1% | 1,948 | $1K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 302 | $1K |
| 86923 | <1% | 29 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 26 | $1K |
| 82805 | <1% | 77 | $976.87 | |
| 0171 | Inj, epinephrine (belcher) | <1% | 270 | $960.36 |
| 94644 | <1% | 113 | $954.57 | |
| 73660 | <1% | 14 | $953.00 | |
| 1159F | <1% | 4,865 | $912.94 | |
| 99205 | Prolong outpt/office vis | <1% | 27 | $850.30 |
| 29130 | <1% | 61 | $738.81 | |
| 73565 | <1% | 92 | $701.39 | |
| 72128 | <1% | 12 | $698.64 | |
| 72110 | <1% | 60 | $681.25 | |
| 99223 | Prolong inpt eval add15 m | <1% | 120 | $591.54 |
| 86304 | <1% | 253 | $581.41 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 54 | $579.20 |
| 74178 | <1% | 12 | $560.23 | |
| 92610 | <1% | 82 | $525.05 | |
| 84100 | <1% | 583 | $524.39 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 16 | $516.14 |
| 74019 | <1% | 71 | $493.69 | |
| 82232 | <1% | 232 | $469.39 | |
| 86301 | <1% | 260 | $419.93 | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 19 | $371.67 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 50 | $349.05 |
| 73120 | <1% | 34 | $342.43 | |
| 92523 | <1% | 13 | $325.15 | |
| 99001 | <1% | 22 | $308.75 | |
| 84132 | <1% | 121 | $256.69 | |
| 76937 | <1% | 78 | $256.64 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $252.12 |
| 0305 | <1% | 2,461 | $245.81 | |
| 0320 | <1% | 175 | $244.10 | |
| C1769 | Guide wire | <1% | 83 | $243.90 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 93 | $243.25 |
| 84403 | <1% | 32 | $242.95 | |
| 87154 | <1% | 15 | $230.38 | |
| 93350 | <1% | 13 | $222.44 | |
| 93308 | <1% | 28 | $219.31 | |
| 0307 | <1% | 1,050 | $174.34 | |
| 0306 | <1% | 1,474 | $172.35 | |
| 0636 | <1% | 205 | $170.16 | |
| 82248 | <1% | 34 | $147.89 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 130 | $141.20 |
| 86780 | <1% | 12 | $136.72 | |
| 83521 | <1% | 112 | $136.06 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 331 | $134.75 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 19 | $132.33 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 130 | $122.43 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 58 | $117.05 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 40 | $116.68 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 33 | $115.30 |
| 73100 | <1% | 16 | $102.62 | |
| 82668 | <1% | 185 | $97.90 | |
| 12001 | <1% | 13 | $87.29 | |
| 85347 | <1% | 101 | $83.73 | |
| A4649 | Surgical supply; miscellaneous | <1% | 437 | $77.63 |
| 73501 | <1% | 13 | $64.98 | |
| 73060 | <1% | 16 | $60.01 | |
| 87045 | <1% | 38 | $58.24 | |
| 11721 | <1% | 12 | $57.36 | |
| 73090 | <1% | 27 | $56.32 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 464 | $53.86 |
| 0730 | <1% | 1,175 | $53.36 | |
| 29515 | <1% | 12 | $52.04 | |
| 70360 | <1% | 13 | $50.09 | |
| 99072 | <1% | 192 | $49.56 | |
| 93246 | <1% | 39 | $42.09 | |
| 84436 | <1% | 118 | $41.53 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 34 | $40.22 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 56 | $32.31 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 51 | $30.78 |
| 36600 | <1% | 24 | $25.89 | |
| 85018 | <1% | 13 | $19.92 | |
| 86334 | <1% | 18 | $19.46 | |
| 82565 | <1% | 44 | $14.67 | |
| 84479 | <1% | 61 | $13.18 | |
| 84520 | <1% | 32 | $13.03 | |
| 86038 | <1% | 27 | $10.42 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $9.90 |
| 87046 | <1% | 13 | $9.40 | |
| 84165 | <1% | 18 | $9.36 | |
| 80069 | <1% | 14 | $9.10 | |
| 0302 | <1% | 218 | $8.47 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 12 | $4.96 |
| 3008F | 0% | 1,826 | $0.00 | |
| 0350 | 0% | 122 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 2,831 | $0.00 |
| 0310 | 0% | 190 | $0.00 | |
| 0949 | 0% | 75 | $0.00 | |
| 0410 | 0% | 297 | $0.00 | |
| 0352 | 0% | 101 | $0.00 | |
| 0255 | 0% | 98 | $0.00 | |
| 0721 | 0% | 95 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| 3074F | 0% | 12 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 13 | $0.00 |
| 0402 | 0% | 130 | $0.00 | |
| 1160F | 0% | 1,068 | $0.00 | |
| 0122 | 0% | 177 | $0.00 | |
| 0278 | 0% | 102 | $0.00 | |
| 84155 | 0% | 31 | $0.00 | |
| 86431 | 0% | 12 | $0.00 | |
| 0489 | 0% | 25 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 84 | $0.00 |
| 3078F | 0% | 120 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 12 | $0.00 |
| 0351 | 0% | 12 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 55 | $0.00 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 12 | $0.00 |
| 99442 | 0% | 12 | $0.00 | |
| 0460 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialISSAI, ALICE (PRESIDENT)